Unicycive Therapeutics is a biotechnology company focused on developing treatments for certain medical conditions. Co.'s existing development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD); and UNI 494, for treatment of acute kidney injury (AKI). CKD is the gradual loss of kidney function that can get worse over time leading to lasting damage. AKI is a sudden episode of kidney failure or kidney damage (within the first 90 days of injury). After 90 days, the patient is considered to have progressed into CKD. We show 11 historical shares outstanding datapoints in our UNCY shares outstanding history coverage, used to compute UNCY market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing UNCY market cap history over the course of time is important for investors
interested in comparing UNCY's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of UNCY versus a peer is one thing; comparing
UNCY market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like UNCY can fluctuate over the course of history.
With this page we aim to empower investors researching UNCY by allowing them to research the UNCY market cap history. |
Free UNCY Email Alerts:
Video: The Importance of Market Cap
